Moreover, two novel selective RET inhibitors, selpercatinib and pralsetinib, have been shown to have potent antitumor activity in thyroid cancer with RET alterations (Wirth et al., 2020; Subbiah et al., 2021). This evidence concerns the gene RET and thyroid gland carcinoma.